Abby Hardy, Author at BioTuesdays

Developments

Canopy Growth to purchase cannabis extract from MediPharm Labs

Canopy Growth (TSX:WEED; NYSE:CGC) has entered an 18-month strategic supply agreement with a unit of MediPharm Labs (TSXV:LABS) to purchase up to 900 kg of cannabis extract. Canopy Growth has committed to purchase a...

November 29, 2018

Developments

Health Canada approves Opsens dPR in coronary heart disease

Health Canada approved Opsens’ (TSX:OPS; OTCQX:OPSSF) diastolic pressure ratio (dPR) proprietary resting index, which measures intracoronary pressure and establishes a diagnosis with the heart at rest to guide treatment...

November 28, 2018

Markets

JP Morgan starts Audentes Therapeutics at OW; PT $35

JP Morgan initiated coverage on Audentes Therapeutics (NASDAQ:BOLD) with an “overweight” rating and December 2019 price target of $35. The stock closed at $23.91 on Nov. 22. “Audentes shares have pulled back 40%-plus...

November 26, 2018

Markets

Mackie ups Bellus Health PT to $2.20 from $1

Mackie Research raised its price target for Bellus Health (TSX:BLU) to $2.20 from $1 after the company reported Phase 1 top-line results of BLU-5937 for the treatment of chronic cough. In the study, BLU-5937...

November 20, 2018

Markets

A.G.P./Alliance ups Titan Pharma PT to 65 cents from 45 cents

A.G.P./ Alliance Global Partners raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to 65 cents from 45 cents after the company’s third quarter results exceeded forecasts. The stock closed at 40 cents on...

November 16, 2018

Markets

Leerink starts Adamas Pharma at OP; PT $20

Leerink Partners launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with an “outperform” rating and $20 price target. The stock closed at $10.84 on Nov. 15. Adamas applies its drug delivery technology to improve...

November 16, 2018

Markets

SVB Financial to acquire Leerink Holdings for $280-million

SVB Financial Group (NASDAQ:SIVB), the parent company of Silicon Valley Bank, agreed to acquire Leerink Holdings for $280 million. Leerink is a Boston-based parent company of Leerink Partners, a leading investment bank...

November 14, 2018

Markets

HCW cuts Trevena to neutral and PT to 75 cents from $3

H.C. Wainwright downgraded Trevena (NASDAQ:TRVN) to “neutral” from “buy” and slashed its price target to 75 cents from $3 after the company received a complete response letter (CRL) on Nov. 2 from the FDA for...

November 5, 2018

Markets

WB starts Celyad at OP; fair market value $53

William Blair launched coverage of Celyad S.A. (NASDAQ:CYAD) with an “outperform” rating and a fair value estimate of $53. The stock closed at $23.58 on Oct.29. Celyad’s lead candidate, CYAD-01, is an autologous...

October 30, 2018

Developments

ContraVir Pharma completes dosing in CRV431 drug-drug interaction study

ContraVir Pharmaceuticals (NASDAQ:CTRV) completed dosing of the last cohort of healthy subjects for its CRV431 drug-drug interaction (DDI) study. The single-dose crossover study evaluated subjects co-treated with...

October 30, 2018

Author - Abby Hardy

Canopy Growth to purchase cannabis extract from MediPharm Labs

Health Canada approves Opsens dPR in coronary heart disease

JP Morgan starts Audentes Therapeutics at OW; PT $35

Mackie ups Bellus Health PT to $2.20 from $1

A.G.P./Alliance ups Titan Pharma PT to 65 cents from 45 cents

Leerink starts Adamas Pharma at OP; PT $20

SVB Financial to acquire Leerink Holdings for $280-million

HCW cuts Trevena to neutral and PT to 75 cents from $3

WB starts Celyad at OP; fair market value $53

ContraVir Pharma completes dosing in CRV431 drug-drug interaction study

Subscribe